Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05117931
Other study ID # 21-324
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date December 2, 2021
Est. completion date November 2025

Study information

Verified date February 2024
Source Memorial Sloan Kettering Cancer Center
Contact Steven Maron, MD
Phone 646-888-6780
Email marons@mskcc.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to see whether the study drug, amivantamab, is an effective treatment for people with EGFR- or MET-amplified esophagogastric cancer. The researchers will also look at whether amivantamab is a safe treatment that causes few or mild side effects in participants.


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date November 2025
Est. primary completion date November 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject or legally authorized representative is willing and able to provide written informed consent. - Patients with previously treated metastatic or unresectable histologically-confirmed esophagogastric cancer who have received at least 1 line of therapy. - EGFR or MET amplification by tissue-NGS with copy number >8 and/or ctDNA amplification by any FDA and CLIA-approved assay - No prior receipt of an EGFR or MET inhibitor for esophagogastric cancer. (Note: if a patient previously received a EGFR inhibitor, but subsequently demonstrated a MET amplification, or previously received a MET inhibitor, but subsequently demonstrated an EGFR-amplification, inclusion is permitted). - Patients with HER2+ (IHC 3+ or IHC 2+/FISH+) tumors must have progressed on trastuzumab. - Measurable disease based on RECIST 1.1. - = 18 years of age on day of signing informed consent. - Have an ECOG performance status of 0, 1, or 2. - Adequate organ function, defined as: A. Hemoglobin =9 g/dL B. ANC =1.0 x 10^9 /L C. Platelets =75 x 10^9 /L D. AST and ALT =3 x ULN (=5 x ULN for subjects with liver metastases) E. Total bilirubin =1.5 x ULN; subjects with Gilbert's syndrome can enroll if conjugated bilirubin is within normal limits F. Serum creatinine <1.5 x ULN or if available, calculated or measured creatinine clearance >50 mL/min/1.73 m^2 - Women of childbearing potential and male patients with women of childbearing potential partners must be willing to use an adequate method of contraception Exclusion Criteria: - Prior chemotherapy, targeted small molecule therapy, or biological therapy, within 2 weeks prior to study day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to a previously administered agent (excluding alopecia). - If subject received major surgery, they must have recovered adequately prior to starting therapy. - Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy. - Known active hepatitis B (e.g., HBsAg reactive or polymerase chain reaction detectable). Note: Subjects with a prior history of HBV demonstrated by positive hepatitis B core antibody are eligible if they have at Screening 1) a negative HBsAg and 2) a HBV DNA (viral load) below the lower limit of quantification, per local testing. Subjects with a positive HBsAg due to recent vaccination are eligible if HBV DNA (viral load) is below the lower limit of quantification, per local testing. - Known active hepatitis C (e.g., HCV RNA [qualitative] is detected). Note: Subjects with a prior history of HCV, who have completed antiviral treatment and have subsequently documented HCV RNA below the lower limit of quantification per local testing are eligible. - Other clinically active or chronic liver disease. - Subject has uncontrolled inter-current illness, including but not limited to poorly controlled diabetes, ongoing or active infection (i.e., has discontinued all antibiotics for at least one week prior to first dose of study drug), or psychiatric illness/social situation that would limit compliance with study requirements. Subjects with medical conditions requiring chronic continuous oxygen therapy are excluded. - Pulmonary embolism (PE) and deep vein thrombosis (DVT), within 1 month of start of study drug. - Myocardial infarction, unstable angina, stroke, transient ischemic attach (TIA), or coronary/peripheral artery bypass graft, or any acute coronary syndrome within 6 months of start of study drug. - Congestive heart failure defined as New York Heart Association (NYHA) Class III-IV or hospitalization for congestive heart failure (any NYHA class) within 6 months of start of study drug. - Interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis requiring treatment with prolonged steroids or other immune suppressive agents that is unresolved or resolved within the last 3 months. - Immune-mediated rash from checkpoint inhibitors that has not resolved prior to enrollment. - Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial, in the opinion of the treating investigator. - Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 6 months after the last dose of trial treatment. - Prisoners, or subjects who are compulsory detained.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Amivantamab
Patients will receive amivantamab weekly for the first cycle, and biweekly subsequently at a dose of 1050mg (<80kg) or 1400mg (>80kg). The first day of dosing is considered Cycle 1 Day 1. Each cycle is 28 days in duration. The initial dose will be administered over 2 days to prevent infusion reactions. For patients who weigh <80 kg, amivantamab 350mg IV will be given on Cycle 1 Day 1, and the remaining 700mg IV will be given on Cycle 1 Day 2. Patients will continue to receive amivantamab 1050mg IV once a week during Cycle 1 then biweekly (Days 1 and 15) of each subsequent Cycle. For patients who weigh = 80 kg, 350mg IV amivantamab will be given on Cycle 1 Day 1 and 1050mg IV will be given on Cycle 1 Day 2. Patients will continue to receive amivantamab 1400mg IV once a week during Cycle 1 then biweekly (Days 1 and 15) of each subsequent Cycle.

Locations

Country Name City State
United States Memorial Sloan Kettering Basking Ridge (Limited protocol activities) Basking Ridge New Jersey
United States Massachusetts General Hospital (Data Collection Only) Boston Massachusetts
United States Memorial Sloan Kettering Commack (Limited Protocol Activities) Commack New York
United States Memorial Sloan Kettering Westchester (Limited Protocol Activities) Harrison New York
United States University of California, Irvine Irvine California
United States Memorial Sloan Kettering Monmouth (Limited protocol activities) Middletown New Jersey
United States Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale New Jersey
United States Memorial Sloan Kettering Cancer Center (All Protocol Activities) New York New York
United States Memorial Sloan Kettering Nassau (Limited protocol activities) Rockville Centre New York
United States Moffitt Cancer Center Tampa Florida

Sponsors (2)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center Janssen Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary objective response rate ORR; defined as complete response (CR) or partial response (PR)) by RECIST 1.1 criteria 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05544929 - A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers Phase 1
Recruiting NCT05612048 - A Study of Tooth Erosion in People With Esophagogastric Cancer N/A
Completed NCT04161781 - A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer
Completed NCT01803282 - Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT05796102 - PET-MRI Esophagus Feasibility Study N/A
Recruiting NCT04656041 - Folfox+Irinotecan+Chemort In Esophageal Cancer Phase 2
Withdrawn NCT02296671 - Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers Phase 2
Active, not recruiting NCT04757363 - A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer Phase 2
Completed NCT02023996 - PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer N/A
Not yet recruiting NCT03760289 - DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer Phase 2
Completed NCT01167114 - STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer Phase 2
Active, not recruiting NCT03133650 - A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing Phase 1